The University of North Carolina at Chapel Hill

Albert Einstein College of Medicine

Victoria Link Limited

Wanda Kay O'Neal

Richard C Boucher

Marcus Mall

Barbara Grubb

Michael R Knowles

Steven Isaacman

Andrew B Mahon

Charles R Esther, Jr

Deepika Polineni

This invention relates generally to the use of 5'-methylthioadenosine phosphorylase (MTAP) inhibitors for the treatment of lung diseases associated with inflammation, such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Small molecule inhibitors of MTAP can sustain accumulation of endogenous MTA to therapeutically beneficial levels resulting in decreased inflammation in CF and COPD.

Use of MTAP inhibitors for the treatment of lung disease

A nonhuman transgenic mammal is described whose genome comprises a promoter construct operably linked to a heterologous DNA encoding an epithelial sodium channel &#x3b2; subunit, wherein said promoter construct directs expression of the epithelial sodium channel &#x3b2; subunit in lung epithelial cells of said animal, and wherein said transgenic mammal has increased lung mucus retention as compared to the corresponding wild-type mammal. The animal is useful in screening compounds for activity in treating lung diseases such as cystic fibrosis and chronic obstructive pulmonary disease.

Animal model for chronic obstructive pulmonary disease and cystic fibrosis

Growing community of inventors

Cary, NC, United States of America

Wanda Kay O'Neal